These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 29361735)
1. Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7-NMDA Receptor Antagonists. Karoutzou O; Kwak SH; Lee SD; Martínez-Falguera D; Sureda FX; Vázquez S; Kim YC; Barniol-Xicota M Molecules; 2018 Jan; 23(1):. PubMed ID: 29361735 [TBL] [Abstract][Full Text] [Related]
2. Discovery, synthesis and SAR of azinyl- and azolylbenzamides antagonists of the P2X₇ receptor. Subramanyam C; Duplantier AJ; Dombroski MA; Chang SP; Gabel CA; Whitney-Pickett C; Perregaux DG; Labasi JM; Yoon K; Shepard RM; Fisher M Bioorg Med Chem Lett; 2011 Sep; 21(18):5475-9. PubMed ID: 21782426 [TBL] [Abstract][Full Text] [Related]
3. Purinergic P2X receptors: structural models and analysis of ligand-target interaction. Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Thomas A; Volpini R Eur J Med Chem; 2015 Jan; 89():561-80. PubMed ID: 25462266 [TBL] [Abstract][Full Text] [Related]
4. Piperazine squaric acid diamides, a novel class of allosteric P2X7 receptor antagonists. Patberg M; Isaak A; Füsser F; Ortiz Zacarías NV; Vinnenberg L; Schulte J; Michetti L; Grey L; van der Horst C; Hundehege P; Koch O; Heitman LH; Budde T; Junker A Eur J Med Chem; 2021 Dec; 226():113838. PubMed ID: 34571173 [TBL] [Abstract][Full Text] [Related]
5. Escape from adamantane: Scaffold optimization of novel P2X7 antagonists featuring complex polycycles. Barniol-Xicota M; Kwak SH; Lee SD; Caseley E; Valverde E; Jiang LH; Kim YC; Vázquez S Bioorg Med Chem Lett; 2017 Feb; 27(4):759-763. PubMed ID: 28126517 [TBL] [Abstract][Full Text] [Related]
6. The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases. Calzaferri F; Ruiz-Ruiz C; de Diego AMG; de Pascual R; Méndez-López I; Cano-Abad MF; Maneu V; de Los Ríos C; Gandía L; García AG Med Res Rev; 2020 Nov; 40(6):2427-2465. PubMed ID: 32677086 [TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship studies of pyrimidine-2,4-dione derivatives as potent P2X7 receptor antagonists. Park JH; Lee GE; Lee SD; Ko H; Kim YC Eur J Med Chem; 2015 Dec; 106():180-93. PubMed ID: 26547056 [TBL] [Abstract][Full Text] [Related]
9. The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease. Mesiti F; Chavarria D; Gaspar A; Alcaro S; Borges F Eur J Med Chem; 2019 Nov; 181():111572. PubMed ID: 31404859 [TBL] [Abstract][Full Text] [Related]
10. P2X7 receptor antagonists for the treatment of systemic inflammatory disorders. Gelin CF; Bhattacharya A; Letavic MA Prog Med Chem; 2020; 59():63-99. PubMed ID: 32362329 [TBL] [Abstract][Full Text] [Related]
11. Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer's Disease: An Update. de Freitas Silva M; Dias KST; Gontijo VS; Ortiz CJC; Viegas C Curr Med Chem; 2018; 25(29):3491-3525. PubMed ID: 29332563 [TBL] [Abstract][Full Text] [Related]
12. Novel Phenyl-Substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 Antagonists with Robust Target Engagement in Rat Brain. Chrovian CC; Soyode-Johnson A; Ao H; Bacani GM; Carruthers NI; Lord B; Nguyen L; Rech JC; Wang Q; Bhattacharya A; Letavic MA ACS Chem Neurosci; 2016 Apr; 7(4):490-7. PubMed ID: 26752113 [TBL] [Abstract][Full Text] [Related]
13. Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT Więckowska A; Kołaczkowski M; Bucki A; Godyń J; Marcinkowska M; Więckowski K; Zaręba P; Siwek A; Kazek G; Głuch-Lutwin M; Mierzejewski P; Bienkowski P; Sienkiewicz-Jarosz H; Knez D; Wichur T; Gobec S; Malawska B Eur J Med Chem; 2016 Nov; 124():63-81. PubMed ID: 27560283 [TBL] [Abstract][Full Text] [Related]
14. Medicinal chemistry of P2X receptors: allosteric modulators. Müller CE Curr Med Chem; 2015; 22(7):929-41. PubMed ID: 25524251 [TBL] [Abstract][Full Text] [Related]
15. Discovery of multitarget-directed ligands against Alzheimer's disease through systematic prediction of chemical-protein interactions. Fang J; Li Y; Liu R; Pang X; Li C; Yang R; He Y; Lian W; Liu AL; Du GH J Chem Inf Model; 2015 Jan; 55(1):149-64. PubMed ID: 25531792 [TBL] [Abstract][Full Text] [Related]
16. P2X7 Receptor: an Emerging Target in Alzheimer's Disease. Huang Q; Ying J; Yu W; Dong Y; Xiong H; Zhang Y; Liu J; Wang X; Hua F Mol Neurobiol; 2024 May; 61(5):2866-2880. PubMed ID: 37940779 [TBL] [Abstract][Full Text] [Related]
18. Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X O'Brien-Brown J; Jackson A; Reekie TA; Barron ML; Werry EL; Schiavini P; McDonnell M; Munoz L; Wilkinson S; Noll B; Wang S; Kassiou M Eur J Med Chem; 2017 Apr; 130():433-439. PubMed ID: 28279849 [TBL] [Abstract][Full Text] [Related]
19. An Investigation on Linker Modifications of Cyanoguanidine-Based P2X7 Receptor Antagonists. Garrett TR; Gilchrist J; McKenzie ADJ; Larik FA; Danon JJ; Werry EL; Kassiou M ChemMedChem; 2024 Sep; 19(17):e202400163. PubMed ID: 38782733 [TBL] [Abstract][Full Text] [Related]
20. P2X7 receptor antagonists protect against N-methyl-D-aspartic acid-induced neuronal injury in the rat retina. Sakamoto K; Endo K; Suzuki T; Fujimura K; Kurauchi Y; Mori A; Nakahara T; Ishii K Eur J Pharmacol; 2015 Jun; 756():52-8. PubMed ID: 25796199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]